Gilead Sciences Announces Strategic Alliance and $5 Billion Contribution
1 report, 1 independent
Updated Sep 21
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Gilead Sciences established a strategic alliance and contributed $5 billion. Concurrent to this, Lakefront Biotherapeutics acquired assets from Ouro Medicines. Lakefront plans to begin registrational trials for its lead T-cell engager, gamgertamig, in 2027, with additional studies expected early that year.
From yahoo.com
Why it matters
Under the agreement, Gilead is expected to commercialize gamgertamig, with Lakefront receiving royalties. The company is focused on a portfolio of four T-cell engager programs. This strategic partnership was supported by Gilead funding, which helped Lakefront announce a €50 million share buyback.
From yahoo.com
Who's involved
- Gilead SciencesStrategic partner in the alliance and contributor of $5 billion to the arrangement.
Keep exploring
The entities involved
-
Gilead Sciences
American company
- Required regulatory filings regarding institutional holdings were made by Gilead Sciences, Inc. with the Securities and Exchange Commission on June 11, 2026.
- A pilot program is underway involving the federal government, Benue State, and Gilead Sciences, with the state participating in the drug supply management.